Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis.

Abstract

Cardiovascular co-morbidity is now a recognised complication of chronic inflammation and an elevated acute phase response predisposes to hypertension, stroke and myocardial infarction. Dyslipidaemia is a feature of inflammatory joint diseases and is closely related to elevated CRP and Il-6 levels. Rheumatoid arthritis (RA) has an increased standardised mortality ratio largely attributable to cardiovascular risk. An increased although lesser, cardiovascular morbidity has also been observed in ankylosing spondylitis (AS) which has a similar abnormal lipid profile to that seen in RA. There is some evidence that therapeutic agents such as anti-tumour necrosis factor-alpha (TNF-alpha) drugs that down-regulate the acute phase response, also have an effect in reducing cardiovascular complications in RA and AS.

• Authors: D McCarey, R D Sturrock
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2009 Jul-Aug Vol. 27 Issue 4 Suppl 55 Pg. S124-6 ISSN: 0392-856X [Print] Italy
• PMID: 19822058 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Cytokines
• Tumor Necrosis Factor-alpha

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (drug therapy, epidemiology, metabolism)
• Cardiovascular Diseases (drug therapy, epidemiology, metabolism)
• Comorbidity
• Cytokines (metabolism)
• Dyslipidemias (drug therapy, epidemiology, metabolism)
• Humans
• Metabolic Syndrome (drug therapy, epidemiology, metabolism)
• Risk Factors
• Spondylitis, Ankylosing (drug therapy, epidemiology, metabolism)
• Synovitis (metabolism)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)